Malaria in the post-genomics era: Light at the end of the tunnel or just another train?

Postgraduate Medical Journal

Volumn 81, Issue 958, 2005, Pages 505-509

  Gardiner, D L ^a   McCarthy, J S ^a   Trenholme, K R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ASPARTIC PROTEINASE INHIBITOR; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; FANSIDAR; MALARIA VACCINE; MEFLOQUINE; QUININE;

GENE SEQUENCE; GENOMICS; HEALTH PROGRAM; HUMAN; LIFE CYCLE; MALARIA; MALARIA CONTROL; MENTAL DISEASE; MORTALITY; MOSQUITO; NEUROLOGIC DISEASE; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTIMALARIALS; GENOMICS; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; MOSQUITO CONTROL; PLASMODIUM FALCIPARUM;

EID: 23844444544     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.030304     Document Type: Review

References (42)

1. Desowitz RS. Malaria capers: more tales of parasites and people, research and reality. London: W W Norton, 1993.
2. Smith DC, Sanford LB. Laveran's germ: The reception and use of a medical discovery. Am J Trop Med Hyg 1984;34:2-20.
3. Manson P. Surgeon Major Ronald Ross's recent investigations on the mosquito malaria theory. BMJ 1898;i:1575-7.
4. Shortt HE, Garnham PCC. Demonstration of a persisting exoerythrocytic cycle in Plasmodium cynomolgi and its bearing on the production of relapses. Trans R Soc Trop Med Hyg 1948;41:785-6.
5. Shortt HE, Fairley NH, Covell G, et al. The pre-erythrocytic stage of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1951;44:405-19.
6. Singh B, Sung LK, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004;363:1017-24.
7. Russell PF. Man's mastery of malaria. London: Oxford University Press, 1955.
8. Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004;4:327-36.
9. Yamey G. Roll back malaria: a failing global health campaign. BMJ 2004;328:1086-7.
10. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419:498-511.
11. Holt RA, Subramanian GM, Halpern A, et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-49.
12. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51.
13. McCarter JP. Genomic filtering: an approach to discovering novel antiparasitics. Trends Parasitol 2004;20:462-8.
14. Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994;88:324-7.
15. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 2004;71(suppl 2):1-15.
16. Peters W. Chemotherapy and drug resistance in malaria. 2nd ed. New York: Academic Press, 1987.
17. Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004;17:235-54.
18. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-94.
19. Olliaro PL, Taylor WR. Antimalarial compounds: from bench to bedside. J Exp Biol 2003;206:3753-9.
20. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J Postgrad Med 2004;50:40-4.
21. Aravind L, Iyer LM, Wellems TE, et al. Plasmodium biology: genomic gleanings. Cell 2003;115:771-85.
22. Skinner-Adams TS, McCarthy JS, Gardiner DL, et al. Antiretrovirals as antimalarial agents. J Infect Dis 2004;190:1998-2000.
23. Collins FH, Kamau L, Ranson HA, et al. Molecular entomology and prospects for malaria control. Bull World Health Organ 2000;78:1412-23.
24. Takken W. Do insecticide-treated bednets have an effect on malaria vectors? Trop Med Int Health 2002;7:1022-30.
25. Maxwell CA, Msuya E, Sudi M, et al. Effect of community-wide use of insecticide-treated nets for 3-4 years on malarial morbidity in Tanzania. Trop Med Int Health 2002;7:1003-8.
26. Curtis CF, Jana-Kara B, Maxwell CA. Insecticide treated nets: impact on vector populations and relevance of initial intensity of transmission and pyrethroid resistance. J Vector Borne Dis 2003;40:1-8.
27. World Health Organisation. Roll back malaria. Africa Malaria Report, 2003. http:www.rbm.who.int/amd2003/amr2003/amr_toc.htm.
28. Lindblade KA, Eisele TP, Gimnig JE, et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA 2004;291:2571-80.
29. Mouchet J. Agriculture and vector resistance. Insect Science and its Application 1988;9:297-302.
30. Greenwood BM. Malaria transmission and vector control. Parasitol Today 1997;13:90-2.
31. Toure YT, Oduola AM, Morel CM. The Anopheles gambiae genome: next steps for malaria vector control. Trends Parasitol 2004;20:142-9.
32. Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature 2002;417:452-5.
33. Clyde DF, Most H, McCarthy VC, et al. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973;266:169-77.
34. Menard R, Sultan AA, Cortes C, et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 1997;385:336-40.
35. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet 2001;358:1927-34.
36. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-20.
37. Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004;189:2213-19.
38. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004;363:150-6.
39. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995;346:462-7.
40. Nosten F, Luxemburger C, Kyle DE, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996;348:701-7.
41. McCarthy M. Preventing pregnancy malaria. Simple vaccines that stop parasites lodging in the placenta may save thousands of lives. Lancet 2004;363:132-3.
42. Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004;71(suppl 2):239-47.